StageSeries A | Alive
About Drug Response Dx
Drug Response Dx is developing a biomarker test kit for rheumatoid arthritis treatment guidance with so-called TNF-alpha inhibitors. The test is secured by a unique patent platform exclusively in-licensed by the Max Planck Society.
Missing: Drug Response Dx's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Drug Response Dx's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Drug Response Dx News
Jan 8, 2013
By FinSMEs Drug Response Dx , a Hennigsdorf, Germany-based developer of proprietary RA biomarkers based on technology licensed from Max-Planck-Innovation , closed itd first round of financing. Founded in February 2012 by Dr. Zoltán Konthur, Dr. Jörg-M. Hollidt, Dr. Karl Skriner and Dr. Joachim Rautter, Drug Response Dx aims to predict efficacy of TNF-alpha inhibitors in rheumatoid arthritis patients. The company intends to use the capital, whose amount was not disclosed, to advance its biomarker test kit for rheumatoid arthritis treatment. A proof of concept is already in place for the antibody-based verification procedure in an ELISA format (Enzyme Linked Immunosorbent Assay). The required biomarkers can also already be produced in high technical quality and fairly large quantities. FinSMEs
Drug Response Dx Frequently Asked Questions (FAQ)
What is Drug Response Dx's latest funding round?
Drug Response Dx's latest funding round is Series A.
Who are the investors of Drug Response Dx?
Investors of Drug Response Dx include High-Tech Grunderfonds and QIAGEN.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.